Antioxidant Biomolecules and Their Potential for the Treatment of Difficult-to-Treat Depression and Conventional Treatment-Resistant Depression
Major depression is a devastating disease affecting an increasing number of people from a young age worldwide, a situation that is expected to be worsened by the COVID-19 pandemic. New approaches for the treatment of this disease are urgently needed since available treatments are not effective for a...
Main Authors: | María Eugenia Riveros, Alba Ávila, Koen Schruers, Fernando Ezquer |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Antioxidants |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3921/11/3/540 |
Similar Items
-
Associations between Melatonin, Neuroinflammation, and Brain Alterations in Depression
by: Eunsoo Won, et al.
Published: (2021-12-01) -
Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression
by: Ines Gallego-Landin, et al.
Published: (2021-12-01) -
Oxidative Stress and Neuroinflammation as a Pivot in Drug Abuse. A Focus on the Therapeutic Potential of Antioxidant and Anti-Inflammatory Agents and Biomolecules
by: Pablo Berríos-Cárcamo, et al.
Published: (2020-09-01) -
Exosomes may be the carrier of acupuncture treatment for major depressive disorder
by: Qin Lyu, et al.
Published: (2023-02-01) -
On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos?
by: Elnaz Roohi, et al.
Published: (2021-02-01)